Client news

A&O Shearman supports GSK on its license agreement with SiranBio

A&O Shearman supports GSK on its license agreement with SiranBio
Published Date
May 6 2026
Related people
Image of Nigel Parker
Nigel ParkerPartner, London
Image of Jill Ge
Jill GePartner, Shanghai
Image of Jessica Delbaum
Jessica DelbaumPartner, New York
Image of Megan McMellon
Megan McMellonSenior Associate, London
Image of Bree Chen
Bree ChenAssociate, Shanghai Lang Yue Law Firm (A&O's joint operation firm in China)
Joanne LiuLegal Advisor, Shanghai
Image of Millie Fantham
Millie FanthamAssociate, London
Image of Regina Loureiro
Regina LoureiroAssociate, Washington DC
A&O Shearman has advised global biopharma GSK on its licensing agreement with Suzhou Siran Biotechnology Co., Ltd., a biotech company specializing in siRNA drug development, under which SiranBio will exclusively license to GSK on a worldwide basis (excluding mainland China, Hong Kong, Macau, and Taiwan) SiranBio’s oligonucleotide candidate (known as “SA030”) targeting metabolic and vascular risk across lung, liver, and kidney disease. 

SiranBio is in the process of conducting phase 1 clinical trials on SA030, following which GSK will assume responsibility for SA030’s development, regulatory filings, and commercialization in the GSK territories.  

The A&O Shearman team was led by IP transactions partner Nigel Parker and senior associate Megan McMellon, supported by IP transactions associate Millie Fantham. Jill Ge, Bree Chen, and Joanne Liu provided valuable PRC support. Jessica Delbaum and Regina Loureiro also provided antitrust support. 

“It is a privilege to continue to support GSK on its complex, cross-border life sciences licensing and collaboration arrangements.”

Related capabilities